Flumatinib

Generic Name: Flumatinib

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₂₉F_₃N_₈O

CAS Number: 895519-90-1

Unique Ingredient Identifier: R4009Y24AI

Overview

Flumatinib has been used in trials studying the treatment of Myelogenous Leukemia, Chronic.

Indication

用于治疗费城染色体阳性的慢性髓性白血病（Ph+CML）慢性期成人患者。

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients	2022/06/27	NCT05433532	Phase 2	Completed	The First Affiliated Hospital of Soochow University
A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase	2022/05/10	NCT05367765	Phase 4	Not yet recruiting	Jiangsu Hansoh Pharmaceutical Co., Ltd.
A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.	2022/04/29	NCT05353205	Phase 4	Recruiting	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL	2021/10/08	NCT05071482	Phase 4	Terminated	Institute of Hematology & Blood Diseases Hospital, China
The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients	2021/06/21	NCT04933526	Phase 4	UNKNOWN	Shenzhen Second People's Hospital
Flumatinib Versus Nilotinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia	2021/02/05	NCT04739826	N/A	Recruiting	The First Affiliated Hospital of Soochow University
Evaluating Efficacy and Safety of Flumatinib for Chronic Phase Chronic Myeloid Leukemia(CML-CP) Without Optimal Response (Warning,Failure) to Imatinib or Dasatinib	2020/12/23	NCT04681820	N/A	Recruiting	Wuhan Union Hospital, China
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure	2020/12/21	NCT04677439	Phase 4	UNKNOWN	Shenzhen Second People's Hospital
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL	2020/05/05	NCT04375683	Phase 3	UNKNOWN	Zhongda Hospital
A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients	2015/07/30	NCT02511340	Phase 2	UNKNOWN	Jiangsu Hansoh Pharmaceutical Co., Ltd.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
Flumatinib Mesylate Tablets	江苏豪森药业集团有限公司	国药准字H20190032	化学药品	片剂	11/22/2019
Flumatinib Mesylate Tablets	江苏豪森药业集团有限公司	国药准字H20190033	化学药品	片剂	11/22/2019

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Related News

Olverembatinib Shows Promise as Second-Line Therapy for Chronic Phase CML

7 months ago

Olverembatinib demonstrates notable efficacy in patients with chronic phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to first-line TKIs.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.